These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32970933)

  • 41. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
    Halabi S; Armstrong AJ; Sartor O; de Bono J; Kaplan E; Lin CY; Solomon NC; Small EJ
    J Clin Oncol; 2013 Nov; 31(31):3944-50. PubMed ID: 24101043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
    BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Anticancer Res; 2019 Aug; 39(8):4411-4414. PubMed ID: 31366538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
    Cicero G; De Luca R; Dorangricchia P; Galvano A; Lo Re G; Serretta V; Dispensa N; Dieli F
    Oncology; 2017; 92(2):94-100. PubMed ID: 27960186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
    Maj-Hes A; Szarvas T; Sevcenco S; Kramer G
    Adv Ther; 2021 Jul; 38(7):3831-3841. PubMed ID: 34043207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
    Conteduca V; Castro E; Wetterskog D; Scarpi E; Jayaram A; Romero-Laorden N; Olmos D; Gurioli G; Lolli C; Sáez MI; Puente J; Schepisi G; Salvi S; Wingate A; Medina A; Querol-Niñerola R; Marin-Aguilera M; Arranz JA; Fornarini G; Basso U; Mellado B; Gonzalez-Billalabeitia E; Attard G; De Giorgi U
    Eur J Cancer; 2019 Jul; 116():158-168. PubMed ID: 31200322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
    Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
    Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
    Mizokami A; Nishimoto K; Matsuyama H; Ichikawa T; Takahashi S; Shiina H; Hashine K; Sugiyama Y; Kamiyama M; Enokida H; Nakajima K
    Anticancer Res; 2022 Mar; 42(3):1465-1475. PubMed ID: 35220240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
    Kessel K; Seifert R; Schäfers M; Weckesser M; Schlack K; Boegemann M; Rahbar K
    Theranostics; 2019; 9(17):4841-4848. PubMed ID: 31410185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).
    Süner A; Aydın D; Hacıoğlu MB; Doğu GG; İmamoğlu GI; Menekşe S; Pilancı KN; Yazıcı ÖK; Koca D; Karaağaç M; Akyol M; Akman T; Ergen S; Avcı N; Kaçan T; Bozkurt O; Kefeli U; Urakçı Z; Araz M; Arpacı E; Harputlu H; Sevinç A
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1238-43. PubMed ID: 27097941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
    J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
    Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
    BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
    Kongsted P; Svane IM; Lindberg H; Sengeløv L
    Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
    Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
    BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.